ATE270544T1 - Halbfeste arzneizubereitung enthaltend isotretinoin - Google Patents

Halbfeste arzneizubereitung enthaltend isotretinoin

Info

Publication number
ATE270544T1
ATE270544T1 AT01969090T AT01969090T ATE270544T1 AT E270544 T1 ATE270544 T1 AT E270544T1 AT 01969090 T AT01969090 T AT 01969090T AT 01969090 T AT01969090 T AT 01969090T AT E270544 T1 ATE270544 T1 AT E270544T1
Authority
AT
Austria
Prior art keywords
semi
preparation containing
medicinal preparation
solid medicinal
isotretinoin
Prior art date
Application number
AT01969090T
Other languages
English (en)
Inventor
Francis Vanderbist
Cecile Servais
Philippe Baudier
Original Assignee
Galephar M F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3862550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE270544(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galephar M F filed Critical Galephar M F
Application granted granted Critical
Publication of ATE270544T1 publication Critical patent/ATE270544T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01969090T 2000-09-22 2001-09-21 Halbfeste arzneizubereitung enthaltend isotretinoin ATE270544T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE0000111 2000-09-22
PCT/BE2001/000163 WO2002024172A1 (en) 2000-09-22 2001-09-21 Pharmaceutical semi-solid composition of isotretinoin

Publications (1)

Publication Number Publication Date
ATE270544T1 true ATE270544T1 (de) 2004-07-15

Family

ID=3862550

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01969090T ATE270544T1 (de) 2000-09-22 2001-09-21 Halbfeste arzneizubereitung enthaltend isotretinoin

Country Status (10)

Country Link
US (5) US7435427B2 (de)
EP (1) EP1318791B1 (de)
AT (1) ATE270544T1 (de)
AU (1) AU2001289438A1 (de)
BR (1) BR102013032172A2 (de)
CA (1) CA2423170A1 (de)
DE (1) DE60104206T2 (de)
ES (1) ES2225600T3 (de)
PT (1) PT1318791E (de)
WO (1) WO2002024172A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2376400A1 (en) 1999-06-08 2000-12-14 University Of Iowa Research Foundation Compounds and methods to enhance raav transduction
US7435427B2 (en) 2000-09-22 2008-10-14 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
ITMI20011338A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio immediato del principio attivo
FI20030426L (fi) * 2003-03-24 2004-09-25 Tomi Jaervinen Syklodekstriinikompleksit
CA2520016A1 (en) 2003-03-31 2004-10-21 University Of Iowa Research Foundation Pharmico-gene therapy of epithelial sodium channel associated disorders
SE0303135D0 (sv) * 2003-11-25 2003-11-25 Lipocore Holding Ab Controlled food effect composition
WO2006102157A1 (en) * 2005-03-21 2006-09-28 Ivax Pharmaceuticals S.R.O. Crystallization inhibitor and its use in gelatin capsules
AU2008215659B2 (en) * 2007-02-16 2012-11-01 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition comprising microparticle oily suspension
RU2392933C2 (ru) * 2008-07-18 2010-06-27 Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН) Средство, обладающее гиполипидемическими свойствами
WO2010109259A1 (es) * 2009-03-26 2010-09-30 Grufarcol Ltda Métoda para preparar formulaciones de gel blando de isotretinoína líquida y la formulaciones obtenidas
SG176097A1 (en) 2009-05-20 2011-12-29 Ranbaxy Lab Ltd Topical retinoid solutions
US10022348B2 (en) 2009-05-20 2018-07-17 Sun Pharmaceutical Industries Limited Topical solution of isotretinoin
CA2762391C (en) 2009-05-20 2017-02-07 Ranbaxy Laboratories Limited Liquid dosage forms of isotretinoin
US9078925B2 (en) 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
AU2014212004B2 (en) * 2013-02-04 2018-09-20 Société des Produits Nestlé S.A. Compositions for treating or preventing or reducing the severity of clostridium difficile related diseases
JP2016535106A (ja) 2013-09-25 2016-11-10 スリーエム イノベイティブ プロパティズ カンパニー 電界グレーディング用組成物
JP6704345B2 (ja) * 2014-01-17 2020-06-03 オンコラル ファーマ エーピーエス 癌治療のためのイリノテカンの固体経口剤形
EP3148644A4 (de) 2014-05-29 2017-12-20 Sun Pharmaceutical Industries Ltd Orale pharmazeutische zusammensetzung aus isotretinoin
RU2016150868A (ru) * 2014-06-02 2018-07-17 Сан Фармасьютикал Индастриз Лимитед Пероральная фармацевтическая композиция изотретиноина
MA40447A (fr) 2014-07-31 2016-02-04 Sun Pharmaceutical Ind Ltd Composition pharmaceutique orale d'isotrétinoïne
US9750711B2 (en) 2014-10-01 2017-09-05 Sun Pharmaceutical Industries Limited Low dose oral pharmaceutical composition of isotretinoin
MA40781A (fr) * 2014-10-01 2017-08-08 Sun Pharmaceutical Ind Ltd Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
WO2016189481A1 (en) * 2015-05-25 2016-12-01 Sun Pharmaceutical Industries Limited Once daily oral pharmaceutical composition of isotretinoin
CA2987517A1 (en) * 2015-05-29 2016-12-08 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
IL322737A (en) 2016-03-07 2025-10-01 Univ Iowa Res Found AAV-mediated expression using a synthetic promoter and enhancer
US10285987B2 (en) 2017-04-28 2019-05-14 Amplipharm Pharmaceuticals, LLC Device and kit for dosing and dispensing non-liquid medicine
CA3062764A1 (en) 2016-04-28 2017-11-02 Amplipharm Pharmaceuticals, LLC Temozolomide powder formulation
US9949967B2 (en) 2016-04-28 2018-04-24 Amplipharm Pharmaceuticals, LLC Temozolomide powder formulation
WO2017203365A1 (en) 2016-05-26 2017-11-30 Dr. Reddy's Laboratiories Ltd. Pharmaceutical compositions for treating acne
WO2017205739A1 (en) 2016-05-26 2017-11-30 University Of Iowa Research Foundation cis AND trans REQUIREMENTS FOR TERMINAL RESOLUTION OF HUMAN BOCAVIRUS 1
WO2018132747A1 (en) 2017-01-13 2018-07-19 University Of Iowa Research Foundation Bocaparvovirus small noncoding rna and uses thereof
WO2018200034A1 (en) * 2017-04-28 2018-11-01 Amplipharm Pharmaceuticals, LLC Device and kit for dosing and dispensing non-liquid medicine
CN111032017A (zh) 2017-06-29 2020-04-17 地平线生物科学有限责任公司 异维a酸口腔粘膜制剂及其使用方法
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
EP4236915A4 (de) * 2020-11-01 2024-10-23 Idrs Labs Pvt Ltd Orale flüssige pharmazeutische zusammensetzungen von isotretinoin
MA69876A1 (fr) 2022-07-01 2025-11-28 Acrotech Biopharma Inc. Compositions pharmaceutiques comprenant de l'isotrétinoïne ainsi que leurs procédés de préparation et leurs utilisations
WO2024236523A1 (en) 2023-05-16 2024-11-21 Sun Pharmaceutical Industries Limited Once daily isotretinoin composition
CN116869940A (zh) * 2023-07-26 2023-10-13 中国科学院上海药物研究所 异维a酸的共晶固体分散体及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA713539B (en) * 1970-06-23 1972-02-23 Hoffmann La Roche Pharmaceutical compositions
US4530213A (en) 1983-06-28 1985-07-23 Air Products And Chemicals, Inc. Economical and thermally efficient cryopump panel and panel array
US4678663A (en) * 1984-02-06 1987-07-07 Nuetrogena Corporation Hydroquinone composition having enhanced bio-availability and percutaneous adsorption
CA1282326C (en) 1984-12-14 1991-04-02 Paul J. Jarosz Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient
US5252604A (en) * 1992-07-10 1993-10-12 Hoffmann-La Roche Inc. Compositions of retinoic acids and tocopherol for prevention of dermatitis
US6054136A (en) 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
US5993585A (en) * 1998-01-09 1999-11-30 Nike, Inc. Resilient bladder for use in footwear and method of making the bladder
US6020003A (en) * 1998-02-23 2000-02-01 Basf Corporation Method of making spray-dried powders with high edible-oil loadings based on non-hydrolyzed gelatin
FR2775597B1 (fr) 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
PE20001227A1 (es) * 1998-10-30 2000-11-06 Hoffmann La Roche Procesos para producir una composicion de isotretinoina
WO2000025572A1 (en) 1998-11-04 2000-05-11 Jagjit Singh Kaurah Improved automatic plant watering system and water level control
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6624154B1 (en) * 1999-04-23 2003-09-23 Bristol-Myers Squibb Company Compositions and methods for treatment of hyperproliferative diseases
EP2269654A3 (de) * 1999-08-24 2011-04-13 Cellgate Inc. Verbesserung des Verabreichung von Arzneimitteln durch und in epitheliale Gewebe rch Verwendung von Oligoarginin-Gruppen
US6267798B1 (en) * 2000-02-02 2001-07-31 Nuflux, Llc Composition for treating steel making slags
IN192188B (de) * 2000-06-16 2004-03-13 Ranbaxy Lab Ltd
US7435427B2 (en) 2000-09-22 2008-10-14 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
CA2762391C (en) 2009-05-20 2017-02-07 Ranbaxy Laboratories Limited Liquid dosage forms of isotretinoin
RU2400226C1 (ru) 2009-06-08 2010-09-27 Юрий Степанович Макляков Способ лечения угревой болезни

Also Published As

Publication number Publication date
ES2225600T3 (es) 2005-03-16
US20080171084A1 (en) 2008-07-17
US20040009225A1 (en) 2004-01-15
DE60104206T2 (de) 2005-09-22
US8367102B2 (en) 2013-02-05
US20130217769A1 (en) 2013-08-22
US8952064B2 (en) 2015-02-10
US20130096196A1 (en) 2013-04-18
EP1318791A1 (de) 2003-06-18
AU2001289438A1 (en) 2002-04-02
DE60104206D1 (de) 2004-08-12
US20130158119A1 (en) 2013-06-20
US7435427B2 (en) 2008-10-14
BR102013032172A2 (pt) 2017-10-24
EP1318791B1 (de) 2004-07-07
CA2423170A1 (en) 2002-03-28
US9089534B2 (en) 2015-07-28
PT1318791E (pt) 2004-11-30
WO2002024172A1 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
BR9810495A (pt) Composição farmacêutica
BR0111016A (pt) Composições farmacêuticas de liberação sustentada para a administração parenteral de compostos hidrófilos biologicamente ativos
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
AR021844A1 (es) Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion
SE0001899D0 (sv) New compounds
BR0015188A (pt) Composições farmacêuticas
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
ATE429210T1 (de) Orale flüssige zusammensetzungen
BR9611802A (pt) Composições farmacêuticas
BR9907647A (pt) Composições contendo composto orgânicos
BR0214679A (pt) Composições farmacêuticas compreendendo compostos a base de vitamina d ativa
HUP9901144A2 (hu) Hatóanyagként klopidogrel és egy antitrombotikum új kombinációját tartalmazó gyógyszerkészítmények
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
ATE530197T1 (de) Medizinische zusammensetzungen zur angiogenese- therapie
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
ATE406161T1 (de) Kombination aus tenofovir, ritonavir und tmc114
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
ATE342734T1 (de) Adenosin a1 antagonisten gegen männliche sterilität
DZ3103A1 (fr) Nouvelles pyrazolo Ä4,3-EÜdiazépines substituées, compositions pharmaceutiques les contenant, utili sation à titre de médicament et procédés pour leurs préparation.
CY1106964T1 (el) Φαρμακα που περιεχουν ν,ν’-διυποκατεστημενες ενωσεις πιπεραζινης και η χρησιμοποιηση τους

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties